Solara Active Pharma Sciences Limited (NSE:SOLARAPP1)
India · Delayed Price · Currency is INR 302.00
+22.20 (7.93%)
At close: Apr 1, 2026
NSE:SOLARAPP1 Revenue
Solara Active Pharma Sciences had revenue of 4.17B INR in the quarter ending September 30, 2026, with 33.11% growth. This brings the company's total for the last twelve months to 15.35B, up 27.30% year-over-year. In the fiscal year ending March 31, 2026, Solara Active Pharma Sciences had annual revenue of 13.69B with 6.64% growth.
Revenue (ttm)
15.35B
Revenue Growth
+27.30%
P/S Ratio
2.04
Revenue / Employee
9.20M
Employees
1,669
Market Cap
31.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 13.69B | 852.20M | 6.64% |
| Mar 31, 2025 | 12.84B | -51.60M | -0.40% |
| Mar 31, 2024 | 12.89B | -1.55B | -10.73% |
| Mar 31, 2023 | 14.44B | 1.75B | 13.83% |
| Mar 31, 2022 | 12.68B | -3.49B | -21.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 19.09B |
| Innova Captab | 17.49B |
| Solara Active Pharma Sciences | 15.35B |
| Windlas Biotech | 9.93B |
| Orchid Pharma | 8.52B |
| RPG Life Sciences | 7.64B |
| Ind-Swift Laboratories | 7.64B |
| Beta Drugs | 4.10B |
Solara Active Pharma Sciences News
- 6 months ago - Solara Active Pharma share price jumps over 4% after USFDA closes Puducherry facility inspection with VAI status - Business Upturn
- 11 months ago - Solara Active Pharma’s Mangalore facility clears US FDA inspection with VAI classification - Business Upturn
- 1 year ago - Solara Active Pharma shares slump nearly 9% today after reporting Q2 net loss - Business Upturn
- 1 year ago - Solara Active Pharma shares rise 4% after Ambernath facility clears USFDA inspection with zero observations - Business Upturn
- 1 year ago - Solara Active Pharma shares down 5% as Managing Director Poorvank Purohit resigns - Business Upturn
- 1 year ago - Solara Active Pharma Sciences announces demerger of CRAMS and Polymers business - Business Upturn
- 1 year ago - Solara Active Pharma Sciences Q3 FY25 Results: Revenue up 41.6% YoY to Rs 300.31 crore - Business Upturn